Tyr239

Site Information
sFCGtVEyMAPEVVN SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 472958
Available spectra: 3 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 )
Disease tissue studied:	lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 ) , non-small cell lung cancer ( 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , non-small cell large cell lung carcinoma ( 4 , 7 ) , non-small cell squamous cell lung carcinoma ( 6 , 10 ) , small-cell lung cancer ( 1 , 2 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 14 ) , A549 (pulmonary) ( 3 ) , Cal-12T (pulmonary) ( 9 ) , Calu-3 (pulmonary) ( 5 ) , DMS153 (pulmonary) ( 8 ) , DMS53 (pulmonary) ( 2 ) , DMS79 (pulmonary) ( 1 ) , HCC15 (pulmonary) ( 6 ) , HCC44 (pulmonary) ( 9 ) , HCC78 (pulmonary) ( 7 ) , HCC827 (pulmonary) ( 5 ) , HeLa (cervical) ( 15 ) , LOU-NH91 (squamous) ( 6 , 11 ) , lung ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , NCI-H128 (pulmonary) ( 1 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1417 (pulmonary) ( 1 ) , NCI-H1437 (pulmonary) ( 8 , 9 ) , NCI-H1650 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 9 ) , NCI-H1703 (squamous) ( 6 , 10 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1781 (pulmonary) ( 7 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H1975 (pulmonary) ( 5 ) , NCI-H2073 (pulmonary) ( 6 , 8 ) , NCI-H209 (pulmonary) ( 1 , 8 ) , NCI-H2106 (pulmonary) ( 5 ) , NCI-H2228 (pulmonary) ( 7 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 6 ) , NCI-H2405 (pulmonary) ( 9 ) , NCI-H3122 (pulmonary) ( 7 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H446 (pulmonary) ( 2 ) , NCI-H460 (pulmonary) ( 4 , 11 ) , NCI-H524 (pulmonary) ( 1 ) , NCI-H526 (pulmonary) ( 2 ) , NCI-H661 (pulmonary) ( 7 ) , NCI-H69 (pulmonary) ( 2 ) , NCI-H82 (pulmonary) ( 2 ) , NCI-H838 (pulmonary) ( 8 )

References
1	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
8	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K (2012) CST Curation Set: 16143; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC) Curated Info
11	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
12	Rikova K (2012) CST Curation Set: 13732; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
13	Rikova K (2012) CST Curation Set: 13734; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
14	Guo A (2009) CST Curation Set: 6257; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631 Curated Info
15	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info